EFFICACY AND TOLERANCE OF 10- AND 7-DAY STANDARD TRIPLE THERAPY IN PATIENTS WITH <i>H. Pylori</i> INFECTION IN THE SMOLENSK REGION: RESULTS OF A RANDOMIZED OPEN COMPARATIVE CLINICAL TRIAL
Objective. The aim of the study was to compare the efficacy of H. pylori eradication and tolerance of 10-day and 7-day of standard triple therapy of H. pylori infection in adults. Methods. In total, 136 H. pylori -infected subjects participated in the randomized clinical trial. 68 patients of the first group received a 10-day standard triple therapy: esomeprazole (20 mg 2 times a day), clarithromycin (500 mg 2 times a day) and amoxicillin (1000 mg 2 times a day). 68 patients of the second group - 7-day standard triple therapy: esomeprazole (20 mg 2 times a day), clarithromycin (500 mg 2 times a day) and amoxicillin (1000 mg 2 times a day). H. pylori stool antigen was performed to check for eradication. Results. The efficacy of H. pylori eradication, according to ITT-analysis, in patients of the first and second groups was 82.4% and 64.7% ( p =0.020), and according to PP-analysis - 87.5% and 66.7% ( p =0.010). Adverse events were reported in 25% of the first group and 36.8% of patients in the second group. There were no statistically significant differences of adverse events in both groups (p>0.05). Conclusion. 10-day standard triple therapy appears to be more effective than 7-day without increasing frequent adverse events. It is not recommended to use 7-day standard triple therapy in the treatment of H. pylori infection in adults in the Smolensk region due to the suboptimal eradication of H. pylori . The use of a 10-day standard triple therapy has extremely acceptable efficacy and can be recommended as a therapy for the first line of H. pylori infection.